Cancer immunotherapy, and in particular the so-called checkpoint inhibitors, have improved the prognosis of several types of tumours. However, they are not effective in everyone. Two early-stage clinical trials have tested the addition of a type of immunomodulator to this therapy in patients with lung cancer and Hodgkin's lymphoma, with apparent good results. The results are published in the journal Science.
Joaquín Martínez López - dos ensayos inmuno EN
Joaquín Martínez López (EN)
Head of the Haematology Department at Hospital 12 de Octubre
The studies are very interesting from a preclinical point of view and of great translational value for the future. The methodology used is very novel. However, the clinical part is still weak due to the small number of patients included.
It is a further demonstration that boosting the action of T lymphocytes increases the response to immunotherapy treatments against cancer.
- Research article
- Peer reviewed
Mathew et al.
- Research article
- Peer reviewed
- Research article
- Peer reviewed
Zak et al.
- Research article
- Peer reviewed
